Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 113.00 | |
25 mg | In stock | $ 247.00 | |
50 mg | In stock | $ 396.00 | |
100 mg | In stock | $ 589.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 76.00 |
Description | JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). |
Targets&IC50 | Androgen receptor:37nM |
In vitro | JNJ-63576253 inhibits the growth of VCaP cells,with an IC50 of 265nM[1]. |
Molecular Weight | 538.97 |
Formula | C23H22ClF3N6O2S |
CAS No. | 2110428-64-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 200mg/mL (371.08 mM)
H2O: insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JNJ-63576253 2110428-64-1 Endocrinology/Hormones Androgen Receptor TRC-253 JNJ63576253 mutant resistant wild-type TRC 253 JNJ 63576253 prostate inhibit castration cancer Inhibitor androgen CRPC LNCaP TRC253 inhibitor